Implications of Inflammatory States on Dysfunctional Immune Responses in Aging and Obesity

Alyssa L. Thomas1,2,3*, Pablo C. Alarcon1,2,3,4*, Senad Divanovic1,2,3,4,5, Claire A. Chougnet1,2,3, David A. Hildeman1,2,3,4,6 and Maria E. Moreno-Fernandez1,2*

1Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, United States, 2Division of Immunobiology Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, United States, 3Immunology Graduate Program and Medical Scientist Training Program, Cincinnati Children’s Hospital Medical Center and The University of Cincinnati College of Medicine, Cincinnati, OH, United States, 4Medical Scientist Training Program, Cincinnati Children’s Hospital Medical Center and The University of Cincinnati College of Medicine, Cincinnati, OH, United States, 5Center for Inflammation and Tolerance, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, United States, 6Center for Transplant Immunology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, United States

Aging and obesity are two conditions characterized by chronic, low-grade inflammation. While both conditions are also associated with dysfunctional immune responses, the shared and distinct underlying mechanisms are just starting to be uncovered. In fact, recent findings have suggested that the effects of obesity on the immune system can be thought of as a state of accelerated aging. Here we propose that chronic, low-grade inflammation seen in obesity and aging is complex, affects multiple cell types, and results in an altered basal immune state. In aging, part of this altered state is the emergence of regulatory immune populations that lead to further immune dysfunction in an attempt to reduce chronic inflammation. While in obesity, part of the altered state is the effect of expanding adipose tissue on immune cell function. Thus, in this review, we compare, and contrast altered immune states in aging and obesity and discuss their potential contribution to a shared clinical problem—decreased vaccine responsiveness.

Keywords: aging, obesity, inflamming, anti-inflamming, immune system, immunosenescence, chronic inflammation

INTRODUCTION

First described in 2000, both chronic, low-grade inflammation, known as “inflamming,” and age-related changes in the immune system, known as immunosenescence, are now recognized as hallmarks of the defective aging immune system (Franceschi et al., 2000a; Franceschi et al., 2000b). Inflamming and immunosenescence create a balancing act that the aging immune system must contend with. These states are associated with increased rates of frailty, cardiovascular disease, Alzheimer’s disease, and susceptibility to infection (Giunta et al., 2008; North and Sinclair, 2012; Monti et al., 2017; Leonardi et al., 2018). Likely as a counter-response to low-grade chronic inflammation, we and others have recently demonstrated that aging also promotes the accumulation of anti-inflammatory cells and molecules, which in turn shape the landscape around age-related immune suppression (Sharma et al., 2006; Almanan et al., 2020).

Chronic inflammation is also a hallmark of obesity. Obesity-associated chronic inflammation is pathophysiologically linked to a variety of adverse sequelae, including metabolic syndrome, type II diabetes (T2D), dyslipidemia, non-alcoholic fatty liver disease (NAFLD), cardiovascular disease,
Alzheimer's disease, and diverse cancers (Calle et al., 2003; Weisberg et al., 2003; Strissel et al., 2007; Schenk et al., 2008). Like in aging, extensive characterization of the immune system in obesity has also revealed alteration of anti-inflammatory mechanisms (Pirola and Ferraz, 2017; Liu and Nikolajczyk, 2019), likely in response to obesity-driven low-grade chronic inflammation.

The immune system in obesity has been posited to display an "immunosenescence" phenotype, similar to that seen in aging (Shirakawa et al., 2016; Salvestrini et al., 2019), where cells become more broadly inflammatory even though their cell-specific functionality is altered. Nonetheless, parallels between the elevated basal rate of inflammation in aged and obesity-related inflammation remain insufficiently explored. It can be posited that the immune cells in aging and obesity become more inflammatory as a manner of trying to compensate for their loss of more specific and targeted functionality. Although immune systems of aged and obese individuals are similar in their inflammatory state, immunomodulatory responses of the immune system are different, suggesting aging and obesity use differing programs to quell the onslaught of inflammatory mediators. Though the pro- and anti-inflammatory responses differ somewhat in aging and obesity, they lead to similar outcomes inclusive of immune system dysfunction.

Notably, the mechanistic similarities and differences between the two chronic inflammatory states remain poorly understood, especially when the two conditions co-exist. In this review, we evaluate and compare inflammatory states of cells and mediators that compromise the aging and obese immune system. For simplicity, we describe their role in obesity and aging as either pro- or anti-inflammatory (Figure 1), although in reality inflammation exists on a sliding scale where each cell or mediator can have either pro- or anti-inflammatory roles given the right context. Finally, we compare the impact of altered immune states in both aging and obesity, utilizing decreased vaccine responsiveness as an exemplar. Furthermore, the underlying immune mechanisms linked to immune dysfunction in aging and obesity are likely to impact many other diseases associated with aging and/or obesity.

**Aging-Associated Chronic Inflammation**

Inflammaging is the chronic low-grade inflammation associated with aging (Franceschi et al., 2000b). Multiple age-associated diseases including cardiovascular diseases, neurodegenerative
and colony stimulating factor (CSF)) (Garmany in 1992; Giuliani et al., 2001; Raynor et al., 2015). There are multiple theories surrounding the underlying mechanism and cellular source of increase inflammaing-associated inflammatory mediators. Senescent cells, obesity, increased gut permeability, changes to microbiota, inflammommasome activation, oxidative stress caused, and chronic infections are likely major contributors. For instance, upon continual cellular stress (e.g., persistent DNA damage signaling, accumulation of reactive oxygen species (ROS), failure to remove defective cellular components) cells can exhibit senescence associated secretory phenotype (SAMP), characterized by cellular growth arrest and a pro-inflammatory secretory phenotype (van Deursen, 2014). Senescent cells secrete many inflammatory mediators (e.g., IL-6, Interleukin-1 (IL-1) and colony stimulating factor (CSF)) (Garfinkel et al., 1994; Coppé et al., 2008), thus their accumulation might be directly responsible for systemic increases in inflammatory proteins with age. In addition, stressed senescent cells produce damage-associated molecular patterns (DAMPs) further activating immune cells pro-inflammatory programming (Huang et al., 2015). Moreover, persistent infections acquired throughout an individual’s lifespan exert a constant pressure on the immune system (Brunner et al., 2011; Minciullo et al., 2016). However, whether the presence of persistent infections contributes to age-related immune senescence remains under debate (Nikolich-Zugich, 2008).

Overall, immune cell functionality declines with aging while exhibiting a bias towards pro-inflammatory phenotypes, further contributing to inflammaing. Aging is associated with a shift in myeloid cells output by the bone marrow; however, these myeloid cells are largely dysfunctional (Pang et al., 2011). Published reports have shown that aged human monocytes shift to a more pro-inflammatory phenotype that correlates with increased production of IL-6, tumor necrosis factor (TNF), and IL-1β compared to their younger counterparts (Sadeghi et al., 1999). Also, neutrophil (Wenisch et al., 2000) and macrophage (Linehan et al., 2014; Wong et al., 2017) phagocytosis decreases with age, preventing bacterial clearance and timely and efficient removal of cellular debris in the case of injury or even normal tissue homeostasis. This results in increased prevalence of DAMPs that further amplifies pro-inflammatory pathways. Similarly, dendritic cell (DC) populations are altered in aging. Aged DCs are less phagocytic and less efficient in the cross-presentation of cell-associated antigens and subsequently in the cross-priming of CD8+ T cells and subsequent effector responses compared to their younger counterparts (Nikolich-Zugich et al., 2012; Chougnnet et al., 2015). The aging T cell compartment produces more inflammatory cytokines compared to their younger counterparts (Fagiolo et al., 1993), and the involuted thymus produces more autoreactive T cells, which are also known to be more inflammatory (Coder et al., 2015). Furthermore, circulating CD4+ T cells from aged individuals display an increased Th17 associated cytokine profile, driven by increased mitochondrial dysfunction and ROS production (Bharath et al., 2020). Together these findings suggest that dysfunction in both the innate and adaptive immune compartments contribute to the inflammaing and immune dysfunction in the elderly.

**Obesity-Induced Chronic Inflammation**

Similar to chronic inflammation in aging, the obese chronic inflammatory state is central to the development of obesity-associated sequelae (e.g., T2D, and NAFLD) (Whitlock et al., 2009; Gregor and Hotamisligil, 2011). While obesity impacts circulating immune cells in both pro- and anti-inflammatory manners, nearly all the cellular populations present within adipose tissue develop an inflammatory phenotype (Elgazar-Carmon et al., 2008; Nishimura et al., 2009; Bertola et al., 2012; Talukdar et al., 2012; Shaikh et al., 2015; Wensveen et al., 2015; Lauterbach and Wunderlich, 2017; Russo and Lumeng, 2018; Zhao et al., 2018). Hence, it is not surprising that adipose tissue expansion is considered the key initiator of inflammation in obesity. The adipose tissue-associated inflammaing microenvironment shapes the chronic, low-grade inflammaing in obesity with both adipose tissue-resident immune cells and inflammaing-skewed adipocytes contributing to the overall effect (Fontana et al., 2007; Reilly and Saltiel, 2017; Chan et al., 2020; Alarcon et al., 2021). Changes in the adipose tissue microenvironment result in increased volume of inflammatory cells and subsequent secretion of inflammatory mediators (e.g., Leptin, IL-6, IL-1β) (Skurk et al., 2007; Strissel et al., 2007; Grant and Dixit, 2015; Wueest and Konrad, 2018). Increased levels of these inflammatory mediators may also contribute to decreased adaptive immune function as plasma from obese individuals is sufficient to induce senescence in cytotoxic T cells (Paris et al., 2017). Of note, as adipose tissue distribution varies by race (Stults-Kolehmainen et al., 2013), such changes could contribute to observed differences in immune responses between obese individuals of diverse races and ethnicities.

The impact of obesity on the innate immune compartment has been the most studied thus far. Published reports have shown increased total numbers of circulating monocytes, macrophages, and neutrophils in obesity (Roberts et al., 2018; Friedrich et al., 2019). Further, these innate immune populations are skewed towards a pro-inflammatory state, with macrophages being skewed towards an inflammaing phenotype and neutrophils having elevated cytokine, reactive oxygen species, and extracellular trap formation, contributing to elevated circulating levels of proinflammaing cytokines (e.g., IL-6, TNFα) (Lumeng, 2013; D’Abbondanza et al., 2019; de Heredia et al., 2012). However, obesity doesn’t impact all immune cells equally. Although increased numbers of DCs are observed in obesity, the chronic inflamaing leads to impaired responsiveness of DCs to toll-like receptor (TLR) agonists (Pizzolla et al., 2016). The obesity-driven inflamaing also negatively impacts effector function of other innate cells (e.g., NK cells), decreasing their total numbers and their cytotoxic potential (O’Shea and Hogan, 2019; Viel et al., 2017).
Intriguingly, the impact of obesity on splenic NK cells closely resembles an aging-induced immunosenescent state (Gheorghe et al., 2017), further supporting the concept of obesity induced “accelerated aging” phenotype (Salvestrini et al., 2019).

Recent studies have also begun to explore obesity’s impact on adaptive immune cell function. Obesity-driven inflammation is also associated with decreased proliferation capability of naïve T cells (James et al., 2012). CD4⁺ helper T cells are skewed towards inflammatory subtypes, with increased Th17 and Th1 (McLaughlin et al., 2017; Moreno-Fernandez et al., 2021a) and decreased Th2 and Treg polarization (Zhao et al., 2018). CD8⁺ T cells are impacted similarly to NK cells, with decreased numbers and limited cytotoxic potential (Kado et al., 2019). In animal models of obesity, increases in adiposity and leukocyte infiltration that occur in the bone marrow negatively impact B cell bone marrow precursor populations (Adler et al., 2014). This results in B cells being skewed towards an inflammatory phenotype (Frasca et al., 2017a). This inflammatory skewing may lead to an increased population of exhausted memory B cells (Frasca et al., 2016; Frasca et al., 2017b), invoking the possibility that obesity-induced inflammatory states further exacerbate deficiencies in antibody responses and subsequently vaccine unresponsiveness. Importantly, B cells accumulate in the adipose tissue as a result of obesogenic diet (Duffaut et al., 2009; Winer et al., 2011). However, in human subcutaneous and visceral adipose tissue only a small fraction of B cells is observed (McDonnell et al., 2012; Garcia-Rubio et al., 2018). Low frequency of B cells can likely be a consequence of low density of fat-associated lymphoid clusters in omental and subcutaneous human adipose tissues, which are structures associated with B cell accumulation. Notably, B cell depletion improved insulin and glucose responses in obesity/T2D, which correlated with decreased inflammation (DeFuria et al., 2013). However, more work is required to mechanistically link chronic adipose tissue inflammation driven by the adaptive immune system to local and systemic immune cell dysfunction/senescent in human disease.

Aging-Associated Immunological Regulation

While aging and obesity are associated with markers of chronic inflammation, both states also lead to altered immunological regulation. Recent work, including findings from our group, have shown that alongside chronic inflammation activation of immune regulatory mechanisms and secretion of anti-inflammatory mediators are exacerbated in aging. Aged mice show an increase in myeloid-derived suppressor cells (MDSCs) in the spleen and peripheral lymph nodes (Heithoff et al., 2008; Enioutina et al., 2011). These aged MDSCs exhibit greater capacity to suppress T cell proliferation and cytotoxic function compared to their younger counterparts (Grizzle et al., 2007; Enioutina et al., 2011). Additionally, macrophages with anti-inflammatory characteristics, including increased secretion of Interleukin-10 (IL-10) and Transforming Growth Factor Beta (TGFβ) are more frequent in aged bone marrow, lymph nodes, and skeletal muscle (Jackaman et al., 2013; Wang et al., 2015).

Regarding the B cell and T cell compartment, regulatory B cells (Bregs) have been shown to increase in aging and conserve their suppressive function by producing similar IL-10 levels compared to young Breg cells (Mori et al., 2016; Freitas et al., 2019). Further, we and others have shown that, in mice and humans, regulatory T cells (Tregs, CD4⁺FOXP3⁺) accumulate with age (Nishioka et al., 2006; Sharma et al., 2006; Lages et al., 2008; Raynor et al., 2012). IL-6 drives the accumulation of Tregs suggesting this is a compensatory pathway attempting to dampen the chronic low-grade inflammation associated with aging (Raynor et al., 2015). Aged Tregs can 1) suppress the activation of DCs via decreased CD86 expression, 2) enhance suppression of effector T cell proliferation, and 3) secrete more IL-10 compared to younger counterparts (Garg et al., 2014). However, aged Tregs fail to suppress Th17 cells’ production of IL-17 during autoimmune inflammation (Sun et al., 2012). Together these data suggest that aging Treg have an altered functional profile.

More recently, we show that IL-10 actively suppresses vaccine responses in aged mice as neutralization of IL-10 restored antigen-specific antibody levels to nearly those observed in young mice (Almanan et al., 2020). In this study, the greatest producer of IL-10 in aged mice was a novel population of T follicular helper cells, which we called Tfh10 cells. These Tfh10 cells appear to regulate the systemic IL-6:IL-10 balance which is crucial to healthy aging (Monti et al., 2017; Almanan et al., 2020). Our data also showed that IL-10R blockade resulted in an increase in antigen-specific, germinal center B cells (Almanan et al., 2020), suggesting this accumulation of Th10 cells in aging is drastically dampening B cell responses. These B cell responses are vital for producing strong antibodies in both a vaccine and infection setting, both of which significantly decrease with age (Frasca and Blomberg, 2011; Simell et al., 2011; Frasca and Blomberg, 2020). Combined, our data suggest that there is active immune suppression in aging, reversible by neutralization of a single cytokine, IL-10, which is sufficient to restore antibody responses in aged mice. Another IL-10 cellular source is T follicular regulatory (Tfr) cells, a novel CD4⁺ T cells population that are FoxP3⁺ and Bcl6⁺ and express high levels of IL-10 in aged mice (Almanan et al., 2020). These aged Tfr cells frequency was reported to be increased in aged mice and humans (Sage et al., 2015; Lefebvre et al., 2016a). Although, at the cellular level Tfr cells were found to display impaired suppressive function due to their age-related decrease in IL-10 production (Lefebvre et al., 2016a; Ito et al., 2019), their suppressive function in aging is associated with expansion. Indeed, we recently reported increased serum IL-10 levels in aged mice (Almanan et al., 2020).

Although inflammmaging is well characterized, there is evidence that both pro- and anti-inflammatory immune programs are present in aging, thus a more detailed investigation of how the anti-inflammatory arm of the immune system is regulated in
aging and how it interacts with age-associated chronic inflammation is needed. Logically, the overabundance of pro-inflammatory mediators that overwhelm an aged individual is bound to elicit a “brake” response, by upregulating anti-inflammatory cells and mediators. Thus, an improved understanding of the interplay of pro- and anti-inflammatory immune programs in aging may provide important insights into overall immune function and potential revitalization in aging.

**Obesity Induced Alteration in Anti-inflammatory Mediators**

Obesity is also associated with alterations in multiple types of immunoregulatory cells and mediators, including Tregs, Bregs, MDSC, anti-inflammatory macrophages and IL-10. While such immune changes plausibly contribute to the persistent low-grade immune activation associated with the obesogenic state, how such changes are modified in elderly obese individuals who have T2D (Cortez-Espinosa et al., 2015) and in the adipose tissue (Wu et al., 2019; Smith et al., 2020). Furthermore, metabolic decline in individuals newly diagnosed with obesity-driven T2D is associated with reduced circulating Treg frequencies (Yuan et al., 2018). In animal models of obesity driven metabolic disease, in homeostatic condition (lean state), Treg cell numbers are expanded in adipose tissue compared to the obesogenic state, where Treg frequency decreased (Feuerer et al., 2009; Bapat et al., 2015). Treg cells play a protective role in insulin sensitivity and energy homeostasis in obesity (Ilan et al., 2010).

Increased adipose inflammation was observed in Treg-depleted mice and altered glucose metabolism was ameliorated in obese mice after adoptive transfer of Treg cells (Feuerer et al., 2009; Eller et al., 2011). As Treg frequency differs in a gender dependent manner (Ishikawa et al., 2020; Vasanthakumar et al., 2020), the impact of obesity on Treg homeostasis may differ between genders. Of note, female mice display lower visceral adipose tissue Treg frequency than male mice (Vasanthakumar et al., 2020). This was associated with estrogen levels, as visceral adipose tissue Tregs frequencies increases in estrogen receptor alpha-depleted or testosterone-treated female mice (Vasanthakumar et al., 2020).

Treg accrual is also reduced in adipose tissue in obese male mice compared to lean animals (Feuerer et al., 2009; Ishikawa et al., 2020). In contrast, obesogenic diet feeding promoted adipose tissue Treg expansion in female mice (Ishikawa et al., 2020), which was associated with limited induction of metabolic diseases (Moreno-Fernandez et al., 2021b). Thus, change in female sex hormones during aging may be implicated in altered adiposity and Treg frequency in the context of increased adiposity during aging. Further, the above mentioned hormonal effect on the immune system may explain lower propensity of females to age-related metabolic alterations in the elderly.

In addition to altered Treg homeostasis, Treg function is impacted in obesity. Numbers of Tregs expressing CD39, an immunomodulatory ecto-5′-nucleotidases, decline in obese individuals who have T2D (Cortez-Espinosa et al., 2015). Importantly, high levels of expression of PD1 and T cell immunoreceptor with Ig and ITIM domains (TIGIT) is observed on Tregs as well as other CD4+ T cells in the adipose tissue of obese humans and mice (Smith et al., 2020; Porsche et al., 2021). However, the role of PD1 pathway is not clear, since PD1 blockade did not affect T cell function and metabolic alteration in obese mice (Porsche et al., 2021). These data suggest that although T cells PD1 is increased additional mechanisms may contribute to T cell exhaustion in obesity.

Increased insulin levels in obesity, a consequence of insulin resistance, may play an important role in shaping Tregs function. Treg sensing of insulin is important as deletion of the insulin receptor in Tregs improved glucose tolerance and insulin sensitivity and increased numbers of IL-10 producing Tregs in adipose tissue of obese animals (Wu et al., 2020). Additionally, insulin administration decreased IL-10-expressing Tregs and diminished Treg capacity to suppress macrophage function (Han et al., 2014). Similarly, levels of leptin, an adipokine, remain high during obesity as a consequence of leptin resistance. Leptin can skew the T cell balance towards an inflammatory state favoring Th17 cell differentiation (Reis et al., 2015) at the expense of Tregs. Hence, circulating leptin levels inversely correlate with circulating Tregs frequency (Wagner et al., 2013). In contrast, levels of adiponectin, another adipokine, are decreased in the obese state (Musovic and Olofsson, 2019). Adiponectin has anti-inflammatory properties that limit production of reactive oxygen species and Th1 cell polarization (Robinson et al., 2011). Combined, these data suggest that increased insulin and leptin in conjunction with decreased adiponectin in the context of obesity likely shifts the balance towards a more pathogenic/pro-inflammatory environment. These responses may influence Treg differentiation and further promote the accrual of inflammatory T cells.

Bregs are also impacted by obesity. Bregs, a subpopulation of B cells characterized by IL-10 production, play a critical role in the differentiation and maintenance of Tregs and in the suppression of T cell responses (Mizoguchi et al., 2000). Obese individuals have a decreased circulating Breg frequency (García-Hernández et al., 2018). In animal models, Breg numbers are decreased in the adipose tissue of obese animals compared to lean controls. Bregs restrict adipose tissue inflammation and insulin resistance in obese mice in an IL-10 dependent manner (Nishimura et al., 2013). Adoptive transfer of adipose tissue Bregs ameliorated those effects and maintained metabolic homeostasis in the lean adipose tissue (Nishimura et al., 2013). Additionally, CD40 or BCR stimulation of purified B cells from obese/T2D subjects led to decreased IL-10 production (Zhai et al., 2016). These data suggest that the impaired ability to secrete IL-10 and TGFβ by B cells in obese and T2D individuals could be linked to decreased Breg numbers and function in obesity and increased overall inflammation. Of note, reduced serum IL-10 levels are observed in patients with obesity-driven T2D (Yuan et al., 2018). IL-10 is a protective factor against diet-induced insulin resistance in the liver and in skeletal muscle as it attenuates macrophage cytokine secretion (Hong et al., 2009). Thus it would be important to determine whether increased IL-10
levels in aging, may play a beneficial role in the context of obesity-driven metabolic disease by ameliorating disease severity (Moreno-Fernandez et al., 2021b). In addition, B cell function is linked with leptin and BAFF levels (Frasca and Blomberg, 2020). BAFF levels are decreased in aging and in obese mice (Jin et al., 2008; Kim et al., 2009). Of note, increased BAFF levels have been implicated in the modulation of weight gain in mice and humans (Chan et al., 2021). Given that aged and obese individuals exhibit reduced antibody responses, the potentially unifying role of BAFF in aging and obesity should be further explored. Likewise, Breg development in obesity could be affected by the impact of obesity in Tfh cells (Garner-Spitzer et al., 2020). A recent study revealed that bariatric surgery (and subsequent weight loss) resulted in an increase of less inflammatory Tfh cells that had better capability to promote the development of Bregs (Zhan et al., 2017), suggesting that Tfh function during obesity is shifted, which may act as a rheostat that regulates overall inflammation.

Contrary to their other immunoregulatory counterparts, MDSC are poorly studied in obesity. Increased frequency of monocyctic CD11b+CD33+CD14+HLADRlow/- MDSC was observed in the peripheral blood of obese individuals (Bao et al., 2015). In mouse models of obesity, a MDSC population expressing Gr-1 and CD11b is highly enriched in the liver and adipose tissue. This particular MDSC population suppressed CD8+ T cell and inflammatory macrophage function in obesity (Xia et al., 2011), suggesting that MDSC may act as another important counter regulatory mechanism of exacerbated inflammatory immune responses in obesity. Overall, though aging and obesity’s effect on immunomodulatory regulation differ, both are associated with immune cell dysfunctionality, leading to abnormal immune responses.

**Inflammation-Induced Immunomodulation: Linking Aging and Obesity**

Intriguing unifying parallels between aging- and obesity-dependent impact in the ability of the immune system to properly function and leading to dysfunctional responses warrant further investigation. Examining these trends is critical for understanding the differences and similarities between the associated-pathologies shared by both states. Of significant interest is the intersection of these two states and how immune alterations differ in those who are both elderly and obese in comparison to those that are only elderly or obese. However, many of the studies perform so far have largely focused on either individual state rather than on overlapping conditions. Therefore, which immunomodulatory program obese elderly individuals adopt, and how this helps them compensate for the compounded chronic inflammation are key questions that remain unanswered. Of note, use of thermoneutral housing allows for studying obesity and aging in unison in both male and female mice (Giles et al., 2017; Moreno-Fernandez et al., 2021b). Thus, this new model may allow for future interrogations of obesity and aging in both sexes and may lead to discovery of new underlying mechanisms linking obesity and aging.

One highly clinically relevant similarity between obesity and aging is their impact on vaccine-driven immune responses. Vaccines have saved hundreds of millions of lives by reducing disease mortality and morbidity. However, both elderly and obese individuals have decreased vaccine responsiveness. For example, yearly influenza vaccines provide 65–80% protection for young individuals while only about 30–50% protection to their older counterparts (Nichol et al., 2007). This lack of protection in aged individuals is largely attributed to age-related dysfunction in B and T cells that leads to a decline in antibody responses to the influenza vaccine (Goronzy et al., 2001; Frasca et al., 2010). Aged B cells accumulate intrinsic defects leading to decreased influenza-specific antibody titers, decreased induction of AID (activation-induced cytidine deaminase), a known inducer of Ig class-switch recombination and somatic hypermutation, and decreased memory induction (Frasca et al., 2010). Additionally, intrinsic defects in aged T cells have been implicated in the loss of influenza vaccine protection. Shifts in the aging CD4+ T cell compartment towards Th1 cells, instead of Th1 cells, have been proposed as a mechanism of decreased vaccine efficacy, as Th1 cells are required for effective influenza clearance in the lung (Lefebvre et al., 2016b). Additionally, as mentioned earlier excessive IL-10 production in aging suppresses vaccine responses in mice (Almanan et al., 2020). Other vaccines show similar decreased efficacy with aging. Hepatitis A and hepatitis B vaccines induce poor antibody responses in the elderly leading to a decrease in vaccine efficacy from 92% in young individuals to 63% for hepatitis A and 67–33% for hepatitis B respectively (Wolters et al., 2003). Additionally, the mRNA-1273 COVID-19 vaccine efficacy drops from 95.6% in individuals under 65 years old to 86.4% in those 65 years and older (Baden et al., 2021). Together, these studies suggest that the altered immune state in aged individuals severely limits their ability to produce adequate and appropriate immune responses, thus leaving these highly vulnerable populations without the protection that vaccines normally provide.

Similar to aged individuals, the impact of obesity on vaccine efficacy is well-reported (Painter et al., 2015). Obese individuals have decreased antibody levels and an overall faster decline in protective levels of antibodies than their lean counterparts for many vaccines including rabies (Bangia et al., 2014), Hepatitis A (Reuman et al., 1997), Hepatitis B (Weber et al., 1985) or tetanus (Fliakim et al., 2006) vaccines. With regards to these normally highly efficient vaccines, obesity-associated chronic inflammation might detrimentally influence the longevity of adaptive immune cells that are known to be impacted by obesity. In addition, obese adults have double the risk of developing influenza-associated pneumonia despite having similar antibody titers to their lean counterparts (Green and Beck, 2017). In this case, worsened disease outcomes (e.g., impaired limitation of viral propagation, lung tissue pathology) have been attributed to the impaired cytotoxicity of NK cells in obese individuals (O’Shea and Hogan, 2019), and/or increased inflammatory propensity of lung macrophages and neutrophils (Narasaraju et al., 2011) in obese individuals. Contribution of obesity-altered adipocytes has also been evoked (Chan et al., 2019; Chan et al., 2020; Chan et al., 2021; Alarcon et al., 2021). This trend might be due to obesity-specific mechanisms, as T2D individuals have similar responsiveness to
the influenza vaccine as non T2D individuals (Sheridan et al., 2015; Dos Santos et al., 2018). Nevertheless, it is important to consider these clinically relevant epidemiological trends, as they might have impact on current and future vaccination efforts, such as for SARS-CoV-2, where obese individuals are an “at risk” group (Popkin et al., 2020).

Although there is some evidence to indicate that aging with comorbidities such as obesity leads to worse outcomes in vaccine efficacy, the interplay between both obesity and aging have been largely understudied. Many reports of vaccine efficacy fail to report data of individuals that are both elderly and obese making it difficult to understand the respective and combined impact of these two states. However, recent preliminary studies have begun to include these analyses. For instance, it was suggested that the Johnson and Johnson COVID-19 vaccine efficacy 28 post vaccination could drop to 42.3% in elderly patients with comorbidities including obesity, compared to 72.4% efficacy in healthy elderly patients and 68.0% in healthy, young adults (Administration FaD, 2021). Hence the combinatory effects of both aging and obesity may exacerbate the worsened immune dysfunctional environment than either obesity or aging alone. Thus, further exploration and data analysis in this area are needed as the obese, elderly, and obese-elderly populations continue to increase.

Importantly, these clinical trends might be attributed to a unifying impact of aging- and obesity-inflammation-dependent skewing of the innate and adaptive immune response. However, we also acknowledge that while chronic inflammation appears to drive any similar immune phenotypes, differences do exist, likely driven by mechanism specific to each state. More research using multimics approaches such as IMM-AGE study (Alpert et al., 2019) will be of great importance to decipher precise unique and share pathways activated in each individual or combine state over time. Further, uncovering of similarities and differences between these two states will also help to uncover whether anti-inflammatory treatment targeted towards amelioration of metabolic dysfunction could be exploitable for aging and/or aging/obesity associated inflammation and improving vaccine responses in these populations. For instance, metformin appears promising for treatment of chronic inflammatory diseases associated with both aging and obesity in pre-clinical models (Bharath et al., 2020). Notably, pioglitazone alone or in combination with metformin has also been shown to have anti-inflammatory properties (Zhang et al., 2008; Shen et al., 2018) and decrease inflammatory mediators in patients with T2D (Forst et al., 2008; Schöndorf et al., 2011). Undeniably, it is attracting to think about repurposing such drugs to improve vaccine efficacy in the elderly and/or obese. For example, preliminary studies of pioglitazone in experimental influenza infection improved survival by favoring protective and limiting exacerbated immune responsiveness in mice (Aldridge et al., 2009; Moseley et al., 2010). A better understanding of these mechanisms is thus imperative to provide better vaccine regimens for obese, elderly, or obese-elderly individuals.

CONCLUDING REMARKS

Aging- and obesity-associated chronic inflammation and potential immunosuppression have a profound impact on the functionality of the immune system (Figure 1A). Both conditions exist as a mixed inflammatory state, where pro- and anti-inflammatory cells and mediators co-exist and contribute to the development of aging- and obesity-associated disease (Figure 1B). While similarities between the aged and obese immune systems have been noted, the literature concerning the impact of combined aged and obese state is limited, something that will be critically important to combat major health issues including vaccine efficacy (Figure 1C). Thus, further examination of the parallels between the aged and obese immune system are needed to identify critical inflammatory mechanistic links. Such studies might provide novel therapeutic approaches to ameliorate the clinical burden of disease in an increasingly obese world that continues to age.

AUTHOR CONTRIBUTIONS

MEM-F, ALT, and PCA contributed equally in the writing of the manuscript. CAC, SD, and DAH contributed equally in editing the manuscript.

FUNDING

This research was supported by Public Health Service Grants AG033057, AG053498, a Catalyst Award from the Falk Foundation (to DH, CC); DK099222 (to SD); CCRF Endowed Scholar Award (to SD); ADA 1-19-PMF-019 (to MM-F) and T32GM063483-14 (associated with PA).

REFERENCES

Adler, B. J., Green, D. E., Pagnotti, G. M., Chan, M. E., and Rubin, C. T. (2014). High fat diet rapidly suppresses B lymphopoiesis by disrupting the supportive capacity of the bone marrow niche. PLoS One 9 (3), e90639. doi:10.1371/journal.pone.0090639
Administration FaD (2021). Janssen Ad26.COV2.S Vaccine for the Prevention of COVID-19. Vaccin. Relat. Biol. Prod. Advisory Committee Meet., 1–62.

Alarcon, P. C., Damen, M., Madan, R., Deepe, G. S., Jr., Spearman, P., Way, S. S., et al. (2021). Adipocyte inflammation and pathogenesis of viral pneumonias: an overlooked contribution. Microbes. ImmunoL. 6, 1–11.
Aldridge, J. R., Jr., Moseley, C. E., Boltz, D. A., Negoveitch, N. J., Reynolds, C., Franks, J., et al. (2009). TNF/iNOS-producing dendritic cells are the necessary evil of lethal influenza virus infection. Proc. Natl. Acad. Sci. 106 (13), 5306–5311. doi:10.1073/pnas.0906055106
Almanan, M., Raynor, J., Ogunsulire, I., Malyshkina, A., Mukherjee, S., Hummel, S. A., et al. (2020). IL-10-producing Tfh cells accumulate with age and link...
inflammation with age-related immune suppression. Sci. Adv. 6 (31), eabb0806. doi:10.1126/sciadv.abb0806
Alpert, A., Pickman, Y., Leipold, M., Rosenberg-Hasson, Y., H. L., Gaujoux, R., et al. (2019). A clinically meaningful metric of immune high-dimensional longitudinal monitoring. Nat. Med. 25 (3), 487–495. doi:10.1038/s41591-019-0381-y
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., et al. (2021). Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. 384 (5), 403–416. doi:10.1056/nejmoa2033589
Banga, N., Guss, P., Banga, A., and Rosenman, K. D. (2014). Incidence and variables associated with inadequate antibody titers after pre-exposure rabies vaccination among veterinary medical students. Vaccine 32 (8), 979–983. doi:10.1016/j.vaccine.2013.12.019
Bao, Y., Mo, J., Ruan, L., and Li, G. (2015). Increased monocytic CD14+/HLA-Flow/γδ myeloid-derived suppressor cells in obesity. Mol. Med. Rep. 11 (3), 2322–2328. doi:10.3892/mmr.2014.2927
Bapat, S. P., Myoung Suh, J., Fang, S., Liu, S., Zhang, Y., Cheng, A., et al. (2015). ‘Abbondanza, M., Martorelli, E. E., Ricci, M. A., De Vuono, S., Migliola, E. N., De Heredia, F. P., Gómez-Martínez, S., and Marcos, A. (2012). Obesity, inflammation and the immune system. Prog. Nutr. Soc. 71 (2), 332–338. doi:10.1017/s009811012000092
DeFuria, J., Belkina, A. C., Jagannath-Bogdan, M., Snyder-Cappione, J., Carr, J. D., Neresova, Y. R., et al. (2013). B cells promote inflammation in obesity and type 2 diabetes through regulation of T-cell function and an inflammatory cytokine profile. Proc. Natl. Acad. Sci. 110 (13), 5133–5138. doi:10.1073/pnas.1215840110
Dos Santos, G., Tahar, H., and Bekkat-Berkani, R. (2018). Immunogenicity, safety, and effectiveness of seasonal influenza vaccination in patients with diabetes mellitus: A systematic review. Hum. Vaccin. Immunother. 14 (8), 1853–1866. doi:10.1080/21645518.2018.1446719
Dufault, C., Galitízký, J., Lafontan, M., and Bouloumié, A. (2009). Unexpected trafficking of immune cells within the adipose tissue during the onset of obesity. Biochem. Biophys. Res. Commun. 384 (4), 482–485. doi:10.1016/j.bbrc.2009.05.002
Elgazar-Carmon, V., Rudich, A., Hadad, N., and Levy, R. (2008). Neutrophils transiently infiltrate intra-abdominal fat early in the course of high-fat feeding. J. Lipid Res. 49 (9), 1894–1903. doi:10.1194/jlr.M800132-JLR200
Eliakim, A., Swindt, C., Zaldívar, F., Casali, P., and Cooper, D. M. (2006). Reduced tetanus antibody titers in overweight children. Autoimmunity 39 (2), 137–141. doi:10.1089/08916930600937326
Elli, K., Kirsch, A., Wolf, A. M., Sopper, S., Tagwerker, A., Stanzl, U., et al. (2011). Potential role of regulatory T cells in reversing obesity-linked insulin resistance and diabetic nephropathy. Diabetes 60 (11), 2954–2962. doi:10.2337/db11-0355
Enquist, N. B., and Stanczyk, F. Z. (2015). Time to use in-vitro rabbit-specific assays to detect antiretroviral drug resistance. Front. Microbiol. 7, doi:10.3389/fmicb.2016.01527
Fagiolo, U., Cossarizza, A., Scala, E., Fanales-Belasio, E., Orlotani, C., Cozzi, E., et al. (1993). Increased cytokine production in mononuclear cells of healthy elderly people. Eur. J. Immunol. 23 (9), 2375–2378. doi:10.1002/eji.1802309590
Feuerer, M., Herrero, L., Cipollotta, D., Naaz, A., Wong, J., Nayer, A., et al. (2009). Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat. Med. 15 (8), 939–939. doi:10.1038/nm.2002
Fontana, L., Eagon, J. C., Trujillo, M. E., Scherer, P. E., and Klein, S. (2007). Visceral Fat Adipokine Secretion Is Associated with Systemic Inflammation in Obese Humans. Diabetes 56 (4), 1010–1013. doi:10.2323/diabetes.106-bb1656
Forst, T., Karagiannis, E., Lübben, G., Hohberg, C., Schönord, T., Dikta, G., et al. (2008). Pleiotropic and anti-inflammatory effects of pioglitazone precede the metabolic activity in type 2 diabetic patients with coronary artery disease. Atherosclerosis 197 (1), 311–317. doi:10.1016/j.atherosclerosis.2007.05.006
Franceschi, C., Bonačič-Koutešić, M., Poljak, I., Zrnić, I., Herceg, V., et al. (2001). Usefulness of the CRP and IL-6 assay in elderly persons: A cross-sectional study. J. Intern. Med. 250 (5), 437–449. doi:10.1046/j.1365-2796.2001.01216.x
Frasca, D., and Blomberg, B. B. (2020). Aging induces B cell defects and decreased antibody responses to influenza infection and vaccination. Immun. Ageing 17 (1), 37–10. doi:10.1186/s12979-020-00210-z
Frasca, D., Blomberg, B. B., and Paganeli, R. (2017). Aging, Obesity, and Inflammatory Age-Related Diseases. Front. Immunol. 8 (1745), 1745. doi:10.3389/fimmu.2017.01745
Frasca, D., and Blomberg, B. B. (2011). Aging affects human B cell responses. J. Clin. Immunol. 31 (3), 430–435. doi:10.1007/s10875-010-9501-7
Frasca, D., Diaz, A., Romero, M., Landin, A. M., and Blomberg, B. B. (2011). Age effects on B cells and humoral immunity in humans. Aging Res. Rev. 10 (3), 330–335. doi:10.1016/j.arr.2010.08.004
Frasca, D., Diaz, A., Romero, M., Landin, A. M., Phillips, M., Lechner, S. C., et al. (2010). Intrinsic defects in B cell response to seasonal influenza vaccination in elderly humans. Vaccine 28 (51), 6077–6084. doi:10.1016/j.vaccine.2010.10.023
Frasca, D., Diaz, A., Romero, M., Vazquez, T., and Blomberg, B. B. (2017). Obesity induces pro-inflammatory B cells and impairs B cell function in old mice. Mech. Ageing Dev. 162, 91–99. doi:10.1016/j.mad.2017.01.004
Frasca, D., Ferracci, F., Diaz, A., Romero, M., Lechner, S., and Blomberg, B. B. (2016). Obesity decreases B cell responses in young and elderly individuals. Obesity 24 (3), 615–625. doi:10.1002/oby.21383
Viel, S., Besson, L., Charrier, E., Marçais, A., Disse, E., Bienvenu, J., et al. (2017). Pioglitazone attenuates aging-related disorders in aged apolipoprotein E deficient mice. Exp. Gerontol. 102, 101–108. doi:10.1016/j.exger.2017.12.002

Sheridan, P. A., Paich, H. A., Handy, J., Karlsson, E. A., Schultz-Cherry, S., Hugdins, M., et al. (2015). The antibody response to influenza vaccination is not impaired in type 2 diabetics. Vaccine 33 (29), 3306–3313. doi:10.1016/j.vaccine.2015.05.043

Shirakawa, K., Yan, X., Shimura, K., Endo, J., Kataoka, M., Katsumata, Y., et al. (2016). Obesity accelerates T cell senescence in murine visceral adipose tissue. J. Clin. Invest. 126 (12), 4626–4639. doi:10.1172/jci86066

Simell, B., Vuorela, A., Ekström, N., Palmu, A., Reunanen, A., Meri, S., et al. (2013). Aging reduces the functionality of anti-pneumococcal antibodies and the killing of Streptococcus pneumoniae by neutrophil phagocytosis. Vaccine 29 (10), 1929–1934. doi:10.1016/j.vaccine.2010.12.121

Skurt, T., Alberti-Huber, C., Herder, C., and Hauner, H. (2007). Relationship between adipocyte size and adipokine expression and secretion. J. Clin. Endocrinol. Metab. 92 (3), 1023–1033. doi:10.1210/jc.2006-1055

Smith, A. J., Liu, J., Yilmaz, A., Wright, V., Bradley, D., and Hsuwe, W. A. (2020). Obesity contributes to a dysfunctional regulatory T cell phenotype within adipose tissue. J. Immunol. 204 (1), 145.

Strissel, K. J., Stancheva, Z., Miyoshi, H., Perfeld, J. W., 2nd, DeFuria, J., Jick, Z., et al. (2007). Adipocyte death, adipose tissue remodeling, and obesity complications. Diabetes 56 (12), 2910–2918. doi:10.2337/db07-0767

Stults-Kolehmainen, M. A., Stanforth, P. R., Bartholomew, J. B., Lu, T., Abolt, C. J., and Sinha, R. (2013). DXA estimates of fat in abdominal, trunk and hip regions varies by ethnicity in men. Nutr. Diabetes 3, e6. doi:10.1038/nutd.2013.5

Sun, L., Hurez, V. J., Thibodeaux, S. R., Kious, M. J., Liu, A., Lin, P., et al. (2012). The role of adipo-myeloid cells in the pathogenesis of metabolic syndrome. J. Biol. Chem. 287 (50), 41530–41540. doi:10.1074/jbc.m111.331513

Vasuathakumar, A., Chisanga, D., Blume, J., Gloury, R., Britt, K., Henstridge, D. C., et al. (2020). Sex-specific adipose tissue imprinting of regulatory T cells. Nature 579 (7800), 581–583. doi:10.1038/s41586-020-2040-3

Vié, S., Besson, J., Charrier, E., Marçais, A., Dese, E., Bienvenu, J., et al. (2017). Alteration of Natural Killer cell phenotype and function in obese individuals. Clin. Immunol. 177, 12–17. doi:10.1016/j.clim.2016.01.007

Wagner, N.-M., Brandhorst, G., Czepluch, F., Lankeit, M., Eberle, C., Herzberg, S., et al. (2013). Circulating regulatory T cells are reduced in obesity and may identify subjects at increased metabolic and cardiovascular risk. Obesity 21 (3), 461–468. doi:10.1111/oby.20087

Wang, Y., Welling-Henricks, M., Samengo, G., and Tidball, J. G. (2015). Increases of M2a macrophages and fibrosis in aging muscle is influenced by bone marrow aging and negatively regulated by muscle-derived nitric oxide. Aging cell 14 (4), 675–688. doi:10.1111/accel.12350

Weber, D. J., Rutala, W. A., Samsa, G. P., Santimaw, J. E., and Lemon, S. M. (1985). Body mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet 337 (8719), 1083–1096. doi:10.1016/S0140-6736(03)63184-4

Winer, D. A., Winer, S., Shen, L., Wadia, P. P., Yanta, J., Palsier, G., et al. (2011). B cells promote insulin resistance through modulation of T cell and production of pathogenic IgG antibodies. Nat. Med. 17 (5), 610–617. doi:10.1038/nm.2353

Wolters, B., Junge, U., Dziuba, S., and Roggendorf, M. (2003). Immunogenicity of combined hepatitis A and B vaccine in elderly persons. Vaccine 21 (25–26), 3623–3628. doi:10.1016/S0264-410X(03)00399-7

Wong, C. K., Smith, C. A., Sakamoto, K., Kaminski, N., Koff, J. L., and Goldstein, D. R. (2017). Aging Impairs Alveolar Macrophage Phagocytosis and Increases Influenza-Induced Mortality in Mice. J.I. 199 (3), 1060–1068. doi:10.4049/jimmunol.1700397

Wu, D., Wang, C. K., Han, J. M., Orban, P. C., Huang, Q., Gillies, J., et al. (2020). T reg-specific insulin receptor deletion prevents diet-induced and age-associated metabolic syndrome. J. Exp. Med. 217 (8), e20191542. doi:10.1084/jem.20191542

Wu, D., Han, J. M., Yu, X., Lam, A. J., Hoeppler, R. E., Pesenacker, A. M., et al. (2019). Characterization of regulatory T cells in obese omental adipose tissue in humans. Eur. J. Immunol. 49 (2), 336–347. doi:10.1002/eji.201847570

Wueest, S., and Konrad, D. (2018). The role of adipocyte-specific IL-6 type cytokine signaling in FFA and leptin release. Agep 7 (3), 226–228. doi:10.1016/bse.2018.4.149301

Xia, S., Sha, H., Yang, L., Ji, Y., Ostrand-Rosenberg, S., and Qi, L. (2011). Gr1+ CD11b+ myeloid-derived suppressor cells suppress inflammation and promote insulin sensitivity in obese. J. Biol. Chem. 286 (26), 23591–23599. doi:10.1074/jbc.m111.237123

Yuan, N., Zhang, H. F., Wei, Q., Wang, P., and Guo, W. Y. (2018). Expression of CD4+CD25+Foxp3+ Regulatory T Cells, Interleukin 10 and Transforming Growth Factor β in Newly Diagnosed Type 2 Diabetic Patients. Exp. Clin. Endocrinol. Diabetes 126 (2), 96–101. doi:10.1055/s-0043-113454

Zhai, X., Qian, G., Wang, Y., Chen, X., Lu, J., Zhang, Y., et al. (2016). Elevated B Cell Activation is Associated with Type 2 Diabetes Development in Obese Subjects. Cell Physiol. Biochem. 38 (3), 1257–1266. doi:10.1159/000443073

Zhan, J., Huang, M., Ma, H., Chen, H., Yang, Y., Tan, S., et al. (2017). Reduced inflammatory responses of follicular helper T cell promote the development of regulatory B cells after Roux-en-Y gastric bypass. Clin. Exp. Pharmacol. Physiol. 44 (5), 556–565. doi:10.1111/cep.12740

Zhang, W. Y., Schwartz, E. A., Permana, P. A., Reaven, P. D., and Reaven, P. (2008). Pioglitazone inhibits the expression of inflammatory cytokines from both monocytes and lymphocytes in patients with impaired glucose tolerance. Arterioscler. Thromb. Vasc. Biol. 28 (6), 2312–2318. doi:10.1161/ATVBHA.108.175687

Zhaa, Y., Lin, L., Xiao, Z., Chen, B., Wan, L., et al. (2018). CD4+ T cells in obesity and obesity-associated diseases. Cell Immunol. 332, 1–6. doi:10.1016/j.cellimm.2018.08.013

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Thomas, Alarcon, Dimanovic, Choungen, Hildeman and Moreno-Fernandez. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.